{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:06:30Z","timestamp":1784268390229,"version":"3.55.0"},"reference-count":25,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: For colon cancer (CC), KRAS mutations are associated with worse outcomes. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced-stage CC may proffer some survival benefits for select patients. We sought to evaluate postoperative morbidity and mortality among mutant and wildtype KRAS patients undergoing CRS\/HIPEC for advanced CC. Methods: We identified 80 patients with CC from an institutional HIPEC database. Patients were categorized based on the presence (mutKRAS) or absence (wildtype) of KRAS mutations. Patient characteristics, tumor factors, treatment, and clinical outcomes were compared between groups. Postoperative morbidity was measured by Clavien\u2013Dindo Classification (CDC). Kaplan\u2013Meier survival analysis evaluated recurrence-free survival (RFS). Results: Overall, 52 (65%) mutKRAS were identified. Patient and tumor characteristics were similar among groups. While not significant, the wildtype group had a lower median (IQR) preoperative PCI score of 7 (3, 12) than the mutKRAS group, whose score was 11 (5, 21) (p = 0.057). The mutKRAS group had a higher rate of CDC grade 3 or more (23.1%) compared to the wildtype group (7.1%) (p = 0.015). Despite this, there were no significant differences in length of stay. Moreover, RFS between the mutKRAS and wildtype groups did not differ significantly (p = 0.47). Conclusions: Contrary to the typical association of KRAS mutations with poorer survival in CC, our findings suggest that patients with this mutation have an RFS comparable to those without it when treated with CRS\/HIPEC. This may imply that CRS\/HIPEC offers therapeutic benefits for KRAS-mutant CC patients, potentially mitigating the usually adverse prognosis associated with this mutation.<\/jats:p>","DOI":"10.3390\/cancers18142301","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:32:17Z","timestamp":1784266337000},"page":"2301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of KRAS Mutation on Recurrence-Free Survival in Colon Cancer Patients Undergoing Cytoreduction with Hyperthermic Intraperitoneal Chemotherapy in a Predominantly Hispanic Population"],"prefix":"10.3390","volume":"18","author":[{"given":"Alexandra E.","family":"Hernandez","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Borowsky","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Cash","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8851-269X","authenticated-orcid":false,"given":"Mariaugusta","family":"Montealegre","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly P.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Noe","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Yadegarynia","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"HCA Florida JFK Hospital, Atlantis, FL 33462, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Pimentel","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bahna","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"HCA Florida JFK Hospital, Atlantis, FL 33462, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-4151","authenticated-orcid":false,"given":"Mecker G.","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Section of Surgical Oncology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2026, July 12). SEER Cancer Statistics Review, 1975\u20132016, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2016\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mendoza-Moreno, F., Diez-Alonso, M., Mat\u00edas-Garc\u00eda, B., Ovejero-Merino, E., G\u00f3mez-Sanz, R., Bl\u00e1zquez-Mart\u00edn, A., Quiroga-Valc\u00e1rcel, A., Vera-Mansilla, C., Molina, R., and San-Juan, A. (2022). Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164922"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: Optimal management review","volume":"25","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_5","first-page":"581","article-title":"Prognostic significance of KRAS gene mutations in colorectal cancer\u2014Preliminary study","volume":"7","author":"Dinu","year":"2014","journal-title":"J. Med. Life"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis","volume":"114","author":"Formica","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1245\/s10434-025-17651-9","article-title":"Great Debate: Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases-Should It Be Offered?","volume":"32","author":"Foster","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sun, B.J., Daniel, S.K., and Lee, B. (2023). The Role of Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Prevention of Peritoneal Metastases in Advanced Colorectal Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206443"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study","volume":"21","author":"Glehen","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Arjona-S\u00e1nchez, A., Barrios, P., Boldo-Roda, E., Camps, B., Carrasco-Campos, J., Concepci\u00f3n Mart\u00edn, V., Garc\u00eda-Fadrique, A., Guti\u00e9rrez-Calvo, A., Morales, R., and Ortega-P\u00e9rez, G. (2018). HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4096-0"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pereira, F., Serrano, A., Manzanedo, I., P\u00e9rez-Viejo, E., Gonz\u00e1lez-Moreno, S., Gonz\u00e1lez-Bay\u00f3n, L., Arjona-S\u00e1nchez, A., Torres, J., Ramos, I., and Barrios, M.E. (2022). GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09572-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/SLA.0000000000001593","article-title":"Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases: A Meta-analysis","volume":"263","author":"Kwakman","year":"2016","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","article-title":"Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC","volume":"27","author":"Graf","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.amjsurg.2016.03.008","article-title":"Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes","volume":"213","author":"Massalou","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_20","unstructured":"Rodriguez-Bigas, M., Lin, E., and Crane, C. (2003). Stage IV colorectal cancer. Holland-Frei Cancer Medicine, BC Decker."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review","volume":"7","author":"Aalbers","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"978394","DOI":"10.1155\/2013\/978394","article-title":"Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy","volume":"2013","author":"Yonemura","year":"2013","journal-title":"Sci. World J."},{"key":"ref_23","unstructured":"Aziz, M.B., and Di Napoli, R. (2023). Hyperthermic Intraperitoneal Chemotherapy. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1245\/s10434-019-07664-6","article-title":"ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?","volume":"27","author":"Graf","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Philipovskiy, A., Ghafouri, R., Kumar Dwinvedi, A., Alvarado, L., McCallum, R., Maegawa, F., Konstantinidis, I.T., Hakim, N., Shurmur, S., and Awasthi, S. (2021). Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients with Metastatic Colorectal Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.772225"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:35:31Z","timestamp":1784266531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":25,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142301"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142301","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}